Sandoz CEO Saynor Signals No Change To Focus Amid Strategic Review
Novartis Unit’s Strategy Remains Unaltered As Parent Company Explores All Options
Executive Summary
Sandoz CEO Richard Saynor says the generics and biosimilars giant’s focus and strategy remain “unchanged” in the wake of a long-awaited announcement by parent company Novartis that it is exploring its options for the Sandoz business.